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Abstract 
 
 Colorectal Cancer (CRC) has been described as the third most common form of 
cancer among men and the second one among women in European Union. The detection of 
CRC, at early stages, is one of the proven strategies resulting in a higher cure rate and, 
although, CRC is one in the small group of cancers which can be prevented by screening, 
only 39% of cases are diagnosed at early stages. In recent years, several studies have 
appeared identifying potential cancer markers in serum, plasma and stool in an attempt to 
improve actual screening procedures. The measurement of MN frequency in peripheral 
blood lymphocytes has been successfully used to identify dietary and genetic factors which 
have a significant impact on genome stability and the utility as a prediction cancer risk tool 
is well documented. On the other hand, it has been demonstrated that epigenetic events, 
altogether with genetic events, plays a crucial role in tumor progression. DNA methylation 
is the most common epigenetic mechanism and consists in a covalent modification of 
DNA. Thus, the aim of the study was (1) Evaluate MN frequency,  (2) Evaluate plasma 
ultrafiltrate capacity to induce MN formation, (3) Evaluate SEPT9 and NOTCH3 promoter 
methylation profile in peripheral blood lymphocytes from subjects resulted positive to fecal 
occult blood test and examined by colonoscopy. 
 MN frequency was significantly higher in subjects with histological diagnosis of 
CRC and adenoma than control (p ≤ 0.001 and p ≤ 0.01, respectively). Also, a statistically 
significant difference in MN frequency was observed between subjects with CRC and 
adenoma (p ≤ 0.001). Relative Risk associated with MN frequency, age, gender, BMI and 
smoke habit, indicate that an elevated MN frequency leads to a 71% increased risk to 
develop adenoma and when associated with an elevated age leads to a 113% increased risk 
for CRC, considering control group as reference. About, CF-MN analysis, a statistically 
significant difference was observed between CRC and control (p ≤ 0.05). On the other 
hand, SEPT9 and NOTCH3 promoter methylation status was significantly lower in CRC 
subjects than controls; additionally, NOTCH3 promoter methylation status was 
significantly lower in CRC subjects than adenoma subjects (p ≤ 0.01). 
 The results obtained allow conclude that MN frequency varies according CRC 
pathologic status and, together with other variables, is a valid biomarker for adenoma and 
CRC risk. Additionally, the plasma of patients affected with CRC not only serve as a 
biomarker for oxidative stress but also as biomarker of genetic damage correlated with the 
carcinogenic process that verifies in colon-rectum. SEPT9 and NOTCH3 promoter 
methylation status, at peripheral blood level, varies according hystopathological changes 
observed in colon-rectum, suggesting that promoter methylation profile of these genes 
could be a reliable biomarker for CRC risk. 
 
Abbreviations 
 
APC     Adenomatous Polyposis Coli gene 
BCL-2     B-cell lymphoma 2 gene 
CIMP     CpG Island Methylatior Phenotype 
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CRC     Colorectal Cancer 
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1. BACKGROUND 
 
1.1 Cancer 
 
1.1.1 General Considerations 
 
 The term cancer refers to several pathologies characterized by an incontrollable 
growth and diffusion of abnormal cells. Cancer is a complex pathology highly variable, 
regarding evolution and outcome, from one individual to another (Merlo et al. 2006). Even 
when it’s an old pathology, it has become a main issue due to the human population growth 
rate and the increased life length expectation, which implies a longer period of exposure to 
carcinogenic agents. 
 
 The American Society of Cancer describes cancer as the second leading cause of 
death in economically developed countries and the third leading cause of death in 
developing countries (Garcia et al. 2007). For 2008 worldwide cancer cases were estimated 
in over 12.6 million and cancer-related death closed to 7.5 million, 20.000 deaths a day 
(Figure 1 and 2). By 2030, it is expected to grow to 21 million new worldwide cancer cases 
and 17.5 million of deaths (Globocan 2008). 
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Figure 1. World cancer incidence by continent (Globocan  2008). 
 
 
Figure 2. World cancer incidence by development status (Globocan 2008). 
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 Risk factors associated with cancer appearance are strictly correlated with life style. 
This is how smoke has been related with different cancers like lung, oral cavity, pharynx, 
larynx and stomach. In developed countries, smoke has been indicated as responsible of 
30% of all kind of cancers. Worldwide, smoke has been described as the most common 
source of carcinogen agents, particularly polycyclic aromatic hydrocarbons and 
nitrosamines (IARC 2004). In the same way, alcohol intake could also favor oral cavity, 
pharynx, larynx, liver, colon, rectum and breast cancer (Boffetta and Hashibe 2006). Diet 
has always been suggested as a possible factor that increases the risk of cancer, and it is 
expected that epidemiological studies may establish a clear relation between this factor and 
increased or decreased cancer risk. However, several studies have shown that, except for 
gastrointestinal cancer types, fat intake, fruit and vegetables, and meat intake are not 
correlated with other types of cancer, like breast or prostate (World Cancer Research Fund 
2007). Additionally, it is well accepted that work exposure to different carcinogens like 
asbestos, polycyclic aromatic hydrocarbons, heavy metals, silica and ionizing radiations are 
associated with an increased cancer risk (IARC 2000, Louis et al. 2007). 
 
 On the other hand, it’s important to highlight that 15 - 20% worldwide cancer cases 
have an infectious origin. Hepatocellular carcinoma caused by hepatitis B or C virus; cervix 
cancer caused by human papilloma virus; lymphoma caused by Epstein-Barr virus; stomach 
cancer caused by Helicobacter pilori, are examples of this particular group (World Cancer 
Report 2008). 
 
 Figure 3 shows the relative contribution of main risk factors according to the 
country develop status. 
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Figure 3. Main cancer risk factors by country develop status (Cancer Atlas 2006). 
 
1.1.2 Tumor development 
 
 Cancer develops from one cell or a small group of cells which must undergo several 
mutations by specific genes (proto-oncogenes and oncosupressor genes) in order to turn 
cancerous. Proto-oncogenes, like RAS, MYC, BCL-2, are generally inactive but after 
several mutations may result activated favoring neoplastic cells proliferation (Rajagopalen 
et al. 2003, Sieber et al. 2003). On the other hand, same mutation of oncosupressor genes, 
like p53, which under normal conditions blocks cell division and induces apoptosis, may 
cause a loss of gene function leading to cell proliferation (Jallepalli and Lengauer 2001, 
Karaman et al. 2008). Indeed, one of the first capabilities acquired by neoplastic cells is to 
grow uncontrollably inducing abnormal cell cloning able to avoid immune system 
surveillance (Miyamoto and Rosenberg 2011). 
 
 Cancer is defined as a progressive pathology. It begins with a small benign lesion 
which remains confined in the original tissue, but in the presence of favorable conditions it 
may evolve into a malignant formation able to spread to surrounding tissues and organs, 
and through blood and lymphatic vessels colonize distant organs to form metastases.
 Three phases are distinguishable during tumor formation: initiation, promotion and 
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progression. During the first one, pre-mutational lesions are produced due to the interaction 
between carcinogens and DNA in an irreversible and dose-independent way. If this damage 
is not repaired before a new division occurs, a mutation may be established, that 
compromises critical genome areas, like proto-oncogenes or oncosupressor genes 
previously mentioned. The second stage, promotion, is characterized by cellular 
hyperproliferation and may be caused by molecules other than those in initiation stage. A 
promoter catalyzes biochemical reactions in both normal and initiated cells, but only in the 
last ones it allows the expression of a new phenotype. This stage is reversible and dose-
dependent. In the last stage, progression, the benign phenotype changes and becomes 
malignant with tumor manifestation (WHO 2000, World Cancer Report 2008). 
 
 
Figure 4. Cancer development: form risk factors to pathology. (World Cancer Report 
2008). 
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1.2 Colorectal Cancer 
 
1.2.1 Epidemiology 
 
 Of different types of cancer, Colorectal Cancer (CRC) has been described as the 
third most common form of cancer among men and the second one among women in the 
European Union (Globocan 2008), and one of the leading causes of cancer-related deaths in 
USA and Europe (Bolognesi et al. 2005) (Figure 5). However, CRC is a world spread 
disease strongly related to life style associated with countrie development situation (Rutter 
et al. 2006, Bonassi et al. 2007, Ferlay et al. 2007, Garcia et al. 2007, World Cancer 
Research Fund 2007) (Figure 6a and 6b). 
 
 
Figure 5. Incidence and mortality by cancer in European Union (Globocan 2008) 
7 
 
 
Figure 6a. International Variation in Age-Standarized Colorectal Cancer Incidence Rates 
Among Males (Globocan 2008). 
 
 
 
Figure 6b. International Variation in Age-Standarized Colorectal Cancer Incidence Rates 
Among females (Globocan 2008). 
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 CRC incidence shows important geographic variations and, as it is possible to 
observe, highest incident rates are seen in North America, Europe, New Zealand, Oceania 
and recently Japan. 
 
 Commonly CRC is diagnosed after 50 – 55 years old and cases that appear before 
40’s are very rare, except for the hereditary syndromes in which tumors could appear even 
earlier, at 10 – 15 years (Mobley et al. 2009) ( Figure 7). 
 
 
Figure 7. Incidence of colorectal cancer by age and sex (Globocan 2008). 
 
 About 75% of CRC cases are defined as sporadic and originate from somatic 
mutations followed by clone develop in the tumor area. The remaining cases could be 
explained as consequence of several pathologies like Familial Adenomatous Polyposis, 
Gardner and Turcot syndrome (1%); Lynch syndrome (4 – 7%); familiar history or 
adenomatous polyp (15 – 20%); chronic inflammatory intestinal diseases or previous 
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diagnosis of cancer like ovarian, endometrial, breast, pancreas or stomach (1%) (WHO 
2000) 
 According to the World Health Organization, different classification systems are 
been used for CRC tumor staging. Originally there was the Dukes classification system, 
which placed patients into one of three categories (Stages A, B, C). This system was 
subsequently modified by Astler-Coller to include a fourth stage (Stage D); Gunderson & 
Sosin subsequently modified it again in 1978. More recently, the American Joint 
Committee on Cancer (AJCC) has introduced the TNM staging system, which places 
patients into one of four stages (Stage I–IV). 
 
Table 1. TNM (Tumor, Node, Metastasis) Staging System for Colorectal 
Cancer 
Tumor  
T1: Tumor invades submucosa. 
T2: Tumor invades muscularis propria. 
T3: Tumor invades through the muscularis propria into the subserosa, or into 
the pericolic or perirectal tissues. 
T4: Tumor directly invades other organs or structures, and/or perforates. 
Node  
N0: No regional lymph node metastasis. 
N1: Metastasis in 1 to 3 regional lymph nodes. 
N2: Metastasis in 4 or more regional lymph nodes.  
Metastasis  
M0: No distant metastasis. 
M1: Distant metastasis present. 
Colorectal Cancer Stage Groupings 
Stage I: T1 N0 M0; T2 N0 M0 
Cancer has begun to spread, but is still in the inner lining.      
Stage II: T3 N0 M0; T4 N0 M0     
Cancer has spread to other organs near the colon or rectum. It has not reached 
lymph nodes. 
Stage III: any T, N1-2, M0 
Cancer has spread to lymph nodes, but has not been carried to distant parts of 
the body. 
Stage IV: any T, any N, M1 
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Cancer has been carried through the lymph system to distant parts of the 
body. This is known as metastasis. The most likely organs to experience 
metastasis from colorectal cancer are the lungs and liver. 
 
 
1.2.2 Colorectal Polyps 
 
 It is well accepted that sporadic CRC cases are preceded by a pre-cancerous lesion 
that could be described as small evagination of the intestinal epithelium due to cellular 
hyper-proliferation. These polyps can be sessile or pedunculated, and some could 
eventually become malignant (Table 2). Indeed, only adenomatous ones are considered pre-
cancerous lesions and close to 25% develop into a malignant tumor. As tumor develops, 
due genetic mutations, specific tissue characteristic are lost, leading to significant changes 
in the intestinal mucosa allowing establishment of the cancerous lesion or adenocarcinoma 
(Figure 8).  
 
Table 2. Classification of Colorectal Polyps (Colucci et al. 2003) 
Histological 
Classification Polyp Type Malignant Potential 
Non-neoplastic 
Hyperplastic polyps 
No 
Hamartomas 
Lymphoid aggregates 
Inflammatory polyps 
Neoplastic (adenomas) 
Tubular adenomas (0–25% 
villous tissue) 
Yes Tubulovillous adenomas (25–75% villous tissue) 
Villous adenoma (75–100% 
villous tissue) 
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1.2.3 Familial Adenomatous Polyposis 
 
 It is an autosomal dominant hereditary genetic syndrome caused by mutation in the 
Adenomatous Polyposis Coli (APC) gene, with the consequent appearing of hundreds of 
adenomatous polyps in the colon rectum. Commonly, these polyps evolve to 
adenocarcinoma about the third decade of patient life (Figure 8). Even when the main signs 
are the polyps (over 100), other signs like mandibular osteoma, congenital hypertrophy of 
the retinal pigment epithelium, dermoid cysts could be present (WHO 2000). 
 
1.2.4 Hereditary Non Polyposis Colorectal Cancer 
 
 It is also an autosomal dominant hereditary syndrome caused by mutations of 
Mismatch Repair genes like MSH2, MLH1, PMS2, MSH6 and MLH3, with MLH1 and 
MSH2 as the most frequently involved genes. Alterations of these genes induce increased 
replication errors leading to microsatellite instability (Huang et al. 1996, WHO 2000, Yi et 
al. 2011). 
 
1.2.5 Familiar Colorectal Cancer 
 
 It includes cases with a previous familiar report of CRC, but which cannot be 
defined as hereditary syndrome, like FAP or HNPCC. It can be classified as simple or 
complex, depending on the age and number of relatives with diagnosis of CRC (WHO 
2000). 
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Figure 8. Colorectal cancer progression, from normal epithelium to adenocarcinoma (Grady 
and Carethers 2008) 
 
1.2.6 Colorectal Cancer Risk Factors 
 
 Risk factors related with CRC consider age, lifestyle and genetics. In developed 
countries, more than 90% of cases are diagnosed in individuals older than 50 years and 
modifiable lifestyle factors like high alcohol consumption, smoking, physical inactivity, 
obesity and diet are associated with an increase risk of CRC (Riccardiello et al. 2003, 
Benassi et al. 2007, Habermann et al. 2009, Garcia et al. 2010). 
 
 Due to the role played by colon and rectum, establish a correlation between diet and 
CRC is extremely important and even when results don’t always agree, it has been 
suggested that a diet high in red or processed meat and an inadequate intake of fruits and 
vegetables increases the risk of CRC (IARC 2002, Riccardiello et al. 2003, Garcia et al. 
2007, World Cancer Research Fund 2007, Habermann et al. 2009). Alcohol intake it also 
been correlated with increased risk of CRC, but the mechanism of action is still unknown 
(Boffetta and Hashibe 2006). 
 
 Recently, it has been proposed that intense physical activity has a protective effect 
only against colon cancer, having no effect on rectum cancer (Spence et al. 2009). 
However, several studies conducted by the IARC and other research centers failed to 
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provide a strong correlation between physical activity and CRC, and benefit obtained from 
it supposed to lie mainly on the ability to increase the intestinal transit, with the consequent 
reduction of exposition time of intestinal mucosa to potential carcinogens present in the 
intestinal content (World Cancer Research Fund 2007). 
 
1.2.6.1 Genetic Instability 
 
 Genetic instability plays an essential role in the development and progression of 
CRC (Lengauer 1998, Karaman et al. 2008). CRC develops through four clinical stages 
(dysplastic crypts, small benign tumors, malignant tumors invading surrounding tissues, 
and metastatic cancer), from a benign small lesion (adenoma) to a malignant tumor 
(carcinoma) through continuous accumulation of genetic and epigenetic alterations, such as 
inactivation of tumor suppressor genes and activation of oncogenes, which induce and 
facilitate uncontrollable cell growth, and they are commonly present in advances stages of 
CRC regardless the possible origin of the pathology (FAP, Lynch syndrome, sporadic) 
(Powell et al. 1992, Carethers 1996, Huang et al. 1996, WHO 2000, Grady and Markowitz 
2002, Riccardiello et al. 2003, Karaman et al. 2008,  Bousserouel et al. 2010).  
 
 Two major types of genetic instability have been described for CRC:  chromosomal 
instability and microsatellite instability (Lengauer 1998, Karaman et al. 2008). Base 
substitution/deletion/insertion, chromosome rearrangement, genic amplification and 
aneuploidy/polyploidy are the most common forms of chromosomal instability (Lengauer 
et al. 1998, Aguilera and Gomez-Gonzales 2008). About 85% of CRCs develop through 
this pathway, which is characterized by aneuploidy as well as loss of heterozygosity 
(Karaman et al. 2008). Mutations of the APC gene are considered the earliest and the most 
prevalent genetic change in colorectal tumorigenesis able to facilitate aneuploidy (Jallepalli 
and Lengauer 2001, Rajagopalen et al. 2003, Sieber et al. 2003). 
 
 On the other hand, microsatellite instability emerges when a lower activity of 
mismatch repair system verifies. Microsatellites, or Simple Sequences Repeats (SSRs), 
length result altered in tumor cells respect to normal cells of the same patient. 
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 Additionally, the DNA double-strand breaks, due to the action of intrinsic or 
extrinsic mutagens, are considered the most critical DNA lesions (Mills et al. 2003, 
Karaman et al. 2008), and it has been suggested that defects in the cellular response to 
double-strand breaks can lead to genetic alteration, chromosomal instability, and ultimately 
malignant transformation as is possible to see in CRC (Mills et al. 2003, Karaman et al. 
2008). 
 
1.2.7 Colorectal Cancer Screening and Diagnosis 
 
 The detection of CRC, at early stages, is one of the proven strategies resulting in a 
higher cure rate (Rutter et al. 2006, Mobley et al. 2009). Although CRC is one in the small 
group of cancers which can be prevented by screening, only 39% of cases are diagnosed at 
early stages (IARC 2008, Mobley et al. 2009). 
 
 Subjects can be divided as at generic, intermediate or high risk, considering age 
(over 50 years old), presence of colon adenomas, relatives with previous diagnose of CRC, 
chronic intestinal diseases, hereditary syndromes or diagnose of other kind of cancers. 
Several studies highlight screening advantages for subjects at generic risk of CRC 
regarding not only the early detection of a treatable lesion, but also the reduction of 
mortality (Levin et al. 2008, Whitlock et al. 2008) The current adopted CRC screening 
procedures include fecal occult blood test (FOBT) and colonoscopy. 
 
 It is known that adenomatous polyps may bleed from the very early stages (IARC 
2002), but even when this condition was present the amount of blood could be so small or 
intermittent, that goes unnoticed to naked eye, while adenomatous polyp continues to 
develop into malignant tumor. This bleeding can be detected through FOBT, who has 
proven to have a sensibility ranged between 60 to 85% and when positive it indicates three 
to four fold increased CRC risk compared with negative one. Normally it is recommended 
to perform FOBT at least every two years and several studies suggest a reduction in 
mortality rate close to 30% (Hardcastle et al. 1996).  
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 The colonoscopy, as a validation test or as screening tool by itself, allows to 
confirms CRC condition with a 90% sensibility and consents full colon rectum inspection 
(Schoenfeld et al. 2005, Regula et al. 2006). Additionally, through colonoscopy it is also 
possible to remove pre cancerous lesions, reducing CRC incidence and mortality. However, 
due to the invasive character and discomfort associated with colonoscopy, patients 
generally reject the test (Bousserouel et al. 2010). 
 
 Other test like X-ray study, sigmoidoscopy or colonography are well described and 
used as screening test, however FOB and colonoscopy offers slight advantage over these 
(Lieberman et al. 2000, Johnson et al. 2008). 
 
 In recent years, several studies have appeared identifying potential cancer markers 
in serum, plasma and stool in an attempt to improve actual screening procedures (Gupta et 
al. 2008, Levin et al. 2008, deVos et al. 2009). 
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1.3 Molecular Epidemiology 
 
 The classic epidemiological approach trough retrospective and prospective studies 
allow to identify and establish possible relations between potential risk factors and a 
particular disease. However, the critical changes that take place after the interaction 
between organism and risk factors remain unknown (Legator and Au 1994, Bolognesi et al. 
2005, Bonassi et al. 2007). In the carcinogenic process, early critical changes are of great 
importance due the fact that they could indicate the establishment and beginning of the 
process (Legator and Au 1994, Bolognesi et al. 2005, Fenech 2008). 
 
 The improvement of molecular biology techniques and more accurate scientific 
instruments have allowed the development of molecular epidemiology. As a discipline, it 
integrates epidemiologic approaches and merges with molecular biology tools in an attempt 
to response unsolved questions opened by traditional epidemiology. 
 
 The objective of molecular epidemiology is to identify and study biomarkers able to 
reflect cellular, molecular and genetic changes that take place at early stages of different 
chronic degenerative diseases. Then, a biomarker can be defined as a molecular or 
biological measurable event able to highlight critical events potentially dangerous for the 
organism. 
 
 Biomarkers can be classified into three main categories: markers of exposure; 
markers of effect, and markers of susceptibility (Bolognesi et al. 2005).The difference 
among them resides in the target that look for, while markers of exposure are centered in 
the risk factor (e.g. a xenobiotic), markers of effect are centered in the biological effect, at 
molecular level (Legator and Au 1994, Bolognesi et al. 2005). On the other hand, markers 
of susceptibility are centered in the genetic characteristics of the biological response of an 
organism faced with a certain risk factor (Legator and Au 1994). A brief class description is 
presented in Table 3. 
 
 
17 
 
 
Table 3. Biomarkers classification 
BIOMARKER CLASS DESCRIPTION 
Exposure 
They can be the xenobiotic itself or a metabolite, or 
a product of xenobiotic interaction, or any other 
event correlated with exposure. They can be divided 
in two subcategories: internal dose and biological 
effective dose. 
Effect 
Any kind of marker able to reflect exposure effect 
over the whole organism or a particular organ 
system. They are considered as preclinical indicators 
and can be specific or nonspecific. 
Susceptibility 
Includes markers indicative of individual sensitivity 
to effects of a particular xenobiotic. They can be 
inherited or induced. 
 
 
1.3.1 Micronuclei Frequency Analysis 
 
 As previously mentioned, genomic instability and/or changes in chromosome 
number has been described as mainly events correlated with cancer etiopathogenesis 
(Legator and Au 1994, Gollin 2005), thus the study of genetic damage biomarkers able to 
highlight this alterations, in different surrogate tissues, are of great interest due to the 
potential application in prevention and public health. 
 
 Micronuclei (MN) (Figure 9) are an early effect biomarker that indicates genome 
damage at cellular level and consist in small fragments of DNA which during mitosis 
remain out of main nucleus constituting little nucleus-like forms (Fenech 2008). The events 
related with MN formation consider chromosome breakage or chromosome malsegregation, 
which could be induced by oxidative stress, exposure to clastogens or aneugens, genetic 
defects in cell cycle checkpoint and/or DNA repair genes, as well as deficiencies in 
nutrients required as co-factors in DNA metabolism and chromosome segregation process 
(Lengauer et al. 1998, Bonassi et al. 2007, Karaman et al. 2008). 
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levels of radiation, like Chernobyl disaster workers and child’s at present days affected by 
radiation related diseases, or patients that have received radiotherapy, have also indicated 
that the MN assay is able to reveal clastogenic activity (Emerit et al. 1997, Ballardin et al. 
2002, Ballardin et al. 2004, Lindholm et al. 2010). Emerit (2007) suggests that it’s possible 
to observe clastogenic factors (i.e. chromosome damaging) activity in circulating plasma of 
subjects affected by different kinds of diseases associated with oxidative stress, including 
radiation exposure, chronic inflammatory diseases, viral infections, ischemia reperfusion 
injury and hereditary chromosomal instability syndromes 
 
1.3.3 Epigenetic Analysis 
 
 Epigenetic (from the Greek, epi-: επί- over, above; and -genetics) corresponds to the 
study of heritable changes in gene expression or in the cellular phenotype caused by 
mechanisms other than changes in the DNA sequence (Feinberg and Tycko 2009). Cellular 
differentiation is a well know example of relevance of epigenetic mechanism. If all cells 
within an organism have the same DNA (Nestler 2009) then the ability to have different 
cells with different functions must be due to a selective activation or silencing of particular 
genes within the genome (Grewal 2003). Actually, it has been demonstrated that epigenetic 
events, altogether with genetic events, play a crucial role in tumor progression (Jordà and 
Peinado 2010). 
 
 Three epigenetic mechanisms are considered the most important ones: genomic 
imprinting, histone modifications and DNA methylation (Feinberg and Tycko 2004). 
Genomic imprinting refers to the relative silencing of one parental allele compared with the 
other parental allele as the consequence of differentially methylated regions within or near 
imprinted genes. Histone modifications, principally acetylation, methylation and 
phosphorylation, are important in the transcriptional regulation, due the ability to induce 
chromatin structure modification, altering DNA accessibility (Feinberg and Tycko 2004). 
DNA methylation is the most common epigenetic mechanism (Jordà and Peinado 2010) 
and consists in a covalent modification of DNA (Figure 10), in which a methyl group is 
transferred from S-adenosylmethionine to the C-5 position of cytosine by a family of 
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cytosine DNA-5-methyltransferases (Feinberg and Tycko 2004) and occurs predominantly 
in the cytosines that precede guanines (CpG) (Bird 1986, Deaton and Bird 2011). 
 
 
Figure 10. Cytosine methylation. 
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1.3.3.1 DNA Methylation 
 
 Even when most human genome lacks of CpG’s, there are short genomic regions 
(500 bp to a few kb) located in the proximal promoter region of approximately 75% of 
human genes rich in CpG nucleotides, called CpG islands (Jordà and Peinado 2010). Most 
of this CpG islands are unmethylated and remains unmethylated at all stages of the 
development and in all tissue types. However a small proportion becomes methylated 
during normal physiological processes and when it happens the associated gene is stably 
silent (Jordà and Peinado 2010, Terry et al. 2011). Methylation regulates gene expression 
not only by altering the interaction of transcription factors to DNA, but also through the 
modification of chromatin conformation (Nan et al. 1998, Jordà and Peinado 2010). In 
recent years, the study of DNA methylation and its role in tumorigenesis has become one of 
the main issues in molecular oncology (Jordà and Peinado 2010, Deaton and Bird 2011).  
 
 Three strategies are commonly used to approach DNA methylation studies, 
digestion of DNA with methylation sensitive or insensitive restriction enzymes, the 
chemical modification of DNA by bisulphite, and the purification of the methylated 
fraction of the genome using antibodies (Jordà and Peinado 2010). Bisulphite-modified 
DNA based studies are the method of choice in most laboratories (Feinberg and Tycko 
2004, Jordà and Peinado 2010, Deaton and Bird 2011) and Polymerase Chain Reaction 
(PCR) analysis, specially through methylation-specific PCR (MSP), is the most widely 
used method to detect CpG-island methylation status (Jordà and Peinado 2010). 
 
 However, under standard PCR conditions, the epigenetic information, as 
methylation pattern, is generally lost because DNA polymerase does not distinguish 
between methylated and non-methylated cytosine, so the polymerase adds a guanine and 
then a non-methylated cytosine in both situations. As a consequence, each originally 
methylated allele is diluted to a concentration impossible to analyze, so the DNA must be 
modified in a way that allows methylated information to remain preserved. Treatment with 
sodium bisulphite, which converts non methylated cytosines into uracil (Clark et al. 1994), 
is used to avoid this problem. 
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 The protocol described by Frommer and colleagues (Frommer et al. 1992, Clark et 
al. 2006) has been widely used for the treatment with sodium bisulphite and when is 
conducted under appropriate conditions, the expected conversion level of unmethylated 
cytosines is about 99% (Clark et al. 1994). Due the fact that the degree of deamination of 
5'-methylcytosine to thymine is much slower than the conversion of cytosine to uracil, it is 
assumed that the only remaining cytosine after treatment with sodium bisulphite are those 
derived from 5'-methylcytosine. During the subsequent PCR, the uracil residues are 
transcribed as Thymine. The procedure is based on the chemical reaction of single-stranded 
DNA with sodium bisulphite (HSO3-) at low pH and high temperatures. The chemical 
reaction of each step is as follows: cytosine carbon-6 sulphonation, irreversible hydrolytic 
deamination of carbon 4 that produces a sulphonate uracil, and finally the following 
desulphonation under alkaline conditions to generate uracil. Methylation of carbon-5 
prevents the carbon-6 sulphonation in the first step of reaction. Although the 5-
methylcytosine can react with sodium bisulphite, this reaction is extremely slow, and the 
balance favors the 5’-methylcytosine rather than thymine (the deamination product of 5’-
methylcytosine). In conclusion, the treatment with sodium bisulphite converts 
unmethylated cytosine of the original strand of DNA to uracil, while methylated cytosines 
remain cytosines (Frommer et al. 1992, Clark et al. 1994 and 2006). 
 
1.3.3.2 DNA Methylation and Colorectal Cancer 
 
 Colorectal Cancer is a well established model for DNA methylation (Carmona and 
Esteller 2011). Using different approaches, a methylation pattern has been identified for 
several genes correlated with CRC (Esteller 2007, Jordà and Peinado 2010). 
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Table 4. Methylation studies of genes correlated with CRC 
Ogino S. et al. 2007 
CACNA1 G voltage-dependent calcium chanel alpha 1 
CDKN2A cyclin-dependent kinase inhibitor 2A 
CRABP1 cellular retinoic acid binding protein 1 
IGF2 insuline growth factor 2 
MLH1 mutL homolog 1 
NEUROG1 neurogenin 1 
RUNX3 runt-related transcriptor factor 3 
SOCS1 suppressor of cytokine signaling 1 
Lofton-Day et al. 
2008 
TMEFF2 tomoregulin 2    
NGFR nerve growth factor receptor 
SPET9 septin 9  
Lee K. -H et al. 
2011 
hMSH2 mutS homolog 2   
MGMT methyl-guanin DNA methyl transferase 
MLH1 mutL homolog 1    
 
 
 Results obtained through these and other studies have detected possible methylation 
patterns correlated with chromosome instability (CIN) and microsatellite instability (MSI), 
previously mentioned as the main genetic pathways that lead to CRC, but have also 
identified a new possible genetic variation named CpG island methylator phenotype 
(CIMP), suggesting a distinct clinicopathological feature with a particular methylation 
pattern (Silver et al. 2011, Zlobec et al. 2011). Additionally, some studies indicate possible 
methylation variations for cancer recurrence risk correlated not only to CRC specific genes 
but also with extra cellular matrix (ECM) pathways (Carmona and Esteller 2011, Yi et al. 
2011), opening up additional areas of research. 
 
 Although the regulation of gene expression by aberrant methylation has been well 
characterized in tumor biology in general and extensively described for CRC (Lofton-Day 
et al. 2008), the vast majority of available studies and literature is referred to tissue-specific 
methylation (Terry et al. 2011). Only in recent years, in an attempt to improve actual CRC 
screening procedures, studies have appeared identifying potential DNA methylation-based 
biomarkers in serum, plasma and stool (deVos et al. 2009, Shivapurkar and Gazdar 2010, 
Ahlquist et al. 2011). 
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 One of the latest DNA methylation-based biomarker for CRC is the plasmatic 
SEPT9 (septin 9 gene) promoter hypermethylation analysis but, even when presented 
positive results in different studies (Lofton-Day et al. 2008, deVos et al. 2009, Tänzer et al. 
2010), some concerns about sensitivity still remain and it has been suggested the stool 
SEPT9 promoter hypermethylaton analysis to minimize this problem (Ahlquist et al. 2011). 
Recently, NEUROG1 and NOTCH 3 have been suggested also as a possible DNA 
methylation-based biomarker (Miyamoto and Rosenberg 2011, Serafin et al. 2011). 
However, further studies must be conducted to validate these biomarkers, as well as to find 
additional ones that helps not only to detect but also to predict disease outcome. 
 
1.3.3.3 Septin 9 (SEPT9) 
 
 Septins are a gene family of cytoskeleton related proteins, encodes cytoplasmic 
GTP binding and hydrolyzing proteins, consisting of 14 members that associate and interact 
with actin and tubulin. They are involved in diverse cellular processes including 
cytokinesis, vesicle trafficking, apoptosis and maintenance of cell polarity (Scott et al. 
2005, Connolly et al. 2011). 
 
 The mechanistic basis for the wide broad of septins functions remains obscure and 
even when most of data about biology and chemistry comes from different organism 
models, particularly in yeast, several lines of evidence suggest a role for septins in the 
development of neoplasia (Scott et al. 2005, Connolly et al. 2011, Peterson et al. 2011). 
Indeed, current available evidence shows a deregulated activity of septins (Scott et al. 
2005). 
 
 In particular, SEPT9 gene has very unique characteristics and has been shown to act 
as an oncogene although tumor suppressor functions have been reported (Table 5) 
(Connolly et al. 2011). In fact, overexpression of SEPT9 has been reported in diverse 
human tumors including breast, central nervous system, endometrium, kidney, liver, lung, 
lymphoid, esophagus, ovary, pancreas, skin, soft tissue and thyroid (Scott et al. 2005). On 
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the other hand, SEPT9 silencing has been reported in colorectal and head and neck cancer 
(Lofton-Day et al. 2008, deVos et al. 2009, Tänzer et al. 2010, Ahlquist et al. 2011). 
 
Table 5. SEPT9 link to cancer (extracted from Connolly et al. 2011) 
Gene Oncogenic   function 
Tumor supressor 
function Tumor type 
SEPT9 
Amplification / 
Overexpression   Breast 
Upregulation Ovary 
Gene fusion AML, ALL 
 Hypermethylation 
Colon, Head 
and Neck 
 Deletion 
Ovary, Breast, 
Hodking 
lymphoma 
AML = acute myeloid leukemia, ALL = acute lymphoblastic leukemia 
 
1.3.3.4 NOTCH3 
 
 Notch genes encode transmembrane receptors (Notch1, 2, 3 and 4) involved in the 
NOTCH signaling pathway (Figure 11), which deregulation has been observed in different 
kind of tumors (Serafin et al. 2011) playing a critical role in maintaining cancer stem cell 
properties (Miyamoto and Rosenberg 2011). The Notch signaling pathway is an 
evolutionarily conserved, intercellular signaling mechanism essential for proper embryonic 
development, due to its demonstrated role in cell differentiation and proliferation 
(Miyamoto and Rosenberg 2011, Serafin et al. 2011).  
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Figure 11. Overview of NOTCH signaling pathway. Notch proteins are single-pass 
receptors with an intracellular domain (NICD). When activated, the NICD translocates to 
the nucleus where interact with different transcription factors leading to activation of Notch 
target genes (source Kyoto Encyclopedia of Genes and Genomes). 
 
 Recent studies have linked Notch1 with Wnt pathway in colon adenomas, and with 
Jagged-1 and DLL ligands expression in CRC (Serafin et al. 2011). However, due the 
importance and complexity of NOTCH pathway, due to the possible cross-talk with 
additional signaling pathways such Wnt, the information available about involvement of 
other Notch receptors in CRC remains insufficient (Miyamoto and Rosenberg 2011, Serafin 
et al. 2011). 
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2. AIM OF THE STUDY 
 
 Main efforts have been made to increase screening rates among population at risk 
for CRC but due the poor patient compliance to current available screening tests, the 
identification and development of new markers obtained from easily accessible tissues, 
leading to a less invasive screening test, have become of great importance (deVos et al. 
2009). Several studies have appeared identifying potential cancer markers in serum, plasma 
and stool in an attempt to improve actual screening procedures (Gupta et al. 2008, Levin et 
al. 2008, deVos et al. 2009). Additionally, continuous improvements of molecular 
techniques have allowed increasing knowledge regarding epigenetic mechanisms and 
carcinogenic process, and one of the latest DNA methylation-based biomarker for CRC is 
the plasmatic SEPT9 promoter hypermethylation analysis (Lofton-Day et al. 2008, deVos 
et al. 2009, Tänzer et al. 2010). However, other genes such NOTCH3 and NEUROG1, 
have been also proposed as potential biomarkers for CRC (Miyamoto and Rosenberg 2011, 
Serafin et al. 2011). Even when great steps have been done to understand CRC, further 
studies are still needed in order to really improve screening and early detection rates 
(Lofton-Day et al. 2008, deVos et al. 2009, Tänzer et al. 2010, Ahlquist et al. 2011). Thus, 
the general objective proposed for the research project has been the identification and 
evaluation of biological effect biomarkers in haematic tissue related with CRC risk. 
 
 In order to achieve this goal, specific objectives have been established: 
 
? To evaluate Micronuclei (MN) frequency in peripheral blood lymphocytes from 
subjects resulted positive to fecal occult blood test (FOBT) and examined by 
colonoscopy. 
 
? To evaluate plasma ultrafiltrate capacity, of subjects resulted positive to fecal occult 
blood test (FBT) and examined by colonoscopy, to induce MN formation (CF-MN) 
in healthy donor peripheral blood lymphocytes. 
 
28 
 
? To evaluate epigenetic modifications correlated with histopathological changes of 
colon-rectum. Particularly, SEPT9 and NOTCH3 promoter methylation profile in 
subjects resulted positive to fecal occult blood test (FOBT) and examined by 
colonoscopy. 
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subjects, 10 females and 13 males); and c) Carcinoma: CRC (26 subjects, 10 females and 
16 males). All the subjects were informed about the study aim according to WMA 
Declaration of Helsinki (World Medical Association 2008) and have provided informed 
consent. Data regarding demographic characteristic, gastrointestinal history, occupational 
history, diet and lifestyle habits have been collected. Body Mass Index (BMI) has been 
included as biological parameter linked to body fatness. 
 
3.2 Blood Sample 
 
 Peripheral blood samples were collected by venipuncture from subjects before 
colonoscopy by medical workers into heparinized tubes and properly coded. Within 1 hour 
of collection, blood samples were centrifuged at 1500 g, for 15 min at 4 °C to obtain the 
plasma and buffy-coat from each sample. Processing and scoring of the samples were 
performed blind and concurrently. At the end of the study, information regarding 
pathological status and recorded data were linked to the code number, becoming available 
for statistical analysis. 
 
3.3 Micronuclei Analysis 
 
 The MN analysis was performed using the cytokinesis-block assay descrived by 
Fenech (Fenech and Morley 1985, Fenech 2007). Peripheral lymphocytes were isolated 
from the buffy-coat of each patient by Histopaque gradient centrifugation (Sigma, St. 
Louis, MO, USA). Cultures were set up using 2 x 106 lymphocytes for each sample in 5 ml 
RPMI 1640 (Sigma) medium, containing 15% fetal calf serum (Sigma), 1% 
phytohaemagglutinin (Sigma), 1mM L-glutamine (Sigma), 100 UI penicillin and 100 µg/ml 
streptomycin (Sigma). Cultures were incubated at 37 °C and 5% CO2 for 72 h. 
Cytochalasin-B (Sigma) was added (final concentration 6 µg/ml) for the last 28 h. Cells 
were collected  and treated with a mild hypotonic treatment (one part RPMI 1640 medium 
and one part distilled water) and fixed with a mixture of methanol/glacial acetic acid. The 
slides were prepared by cytocentrifugation, air-dried and then stained by conventional May-
Grünwald Giemsa staining (Sigma). Cell-cycle parameters were evaluated by the nuclear 
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division index (NDI). This index was calculated by scoring at least 1000 cells for the 
presence of one, two, three or more nuclei according the following formula: NDI = (1M1 + 
2M2 + 3M3 + 4M4)/n, where M1 – M4 indicates the number of cells with 1 – 4 nuclei and n 
indicates the total number of cells scored. MN were scored using a Zeiss Axioplan 
microscope at 1000X and, in accordance with standard criteria, 2000 binucleated 
lymphocytes were evaluated for each patient (Fenech 2007). 
 
3.4 Clastogenic Factors (CF) Analysis 
 
 An aliquot of plasma from each patient was ultrafiltered at 800 g for 2 hours using 
Centriplus tubes, with 10 kDa cutoff (Millipore). This procedure removes all high-
molecular-weight plasma components that might disturb culture growth because of blood 
group incompatibilities. In addition, it eliminates cells that might still be present in the 
plasma after centrifugation. The plasma ultrafiltrate from each patient was immediately 
frozen at −80 °C until use. CF-MN analysis was also performed using the cytokinesis-block 
technique. In this case, peripheral lymphocytes were isolated from a buffy-coat of a healthy 
no-smoker male provided by AVIS (Italian Association of Voluntary Blood donors) using a 
density gradient (Histopaque, Sigma). Lymphocytes cultures were set up by incubating 2 x 
106 cells in 5 ml RPMI 1640 (Sigma) medium, containing 15% fetal calf serum (Sigma), 
1% phytohaemagglutinin (Sigma), 1mM L-glutamine (Sigma), 100 UI penicillin and 100 
µg/ml streptomycin (Sigma), and 100 µl of plasma ultrafiltrate obtained from each subject 
were added to paired lymphocytes cultures. After 44 h, all cultures were supplemented with 
cytochalasin-B (final concentration 6 µg/ml). At the end of 72 h incubation, cells were 
collected and treated with a mild hypotonic treatment (one part RPMI 1640 medium and 
one part distilled water) and fixed with a mixture of methanol/glacial acetic acid. The slides 
were prepared by cytocentrifugation, air-dried and then stained by conventional May-
Grünwald Giemsa staining (Sigma). CF-MN were scored as mentioned previously. 
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3.5 Cell Culture 
 
 Additionally, CaCo2 cells (Istituto Zooprofilattico della Lombardia e dell’Emilia, 
Iatly) were cultured in Dulbecco’s Modified Eagle Medium (Lonza, Basel, Switzerland) 
with 20% fetal calf serum (Lonza) and 1mM L-glutamine (Sigma), 100 UI penicillin and 
100 µg/ml streptomycin (Sigma). Cultures were done in triplicates. At the end of culture, 
cells were Trypsinized (0.25% Trypsin-EDTA solution, Sigma), counted and divided in 
aliquots up to 5 x 106 cells. 
 
3.6 DNA extraction and purification 
 
 DNA was extracted from 100 µl of whole blood, plasma and CACO2 cells using ZR 
Genomic DNA (Zymo Research, Irvine, CA, USA) following manufacturer’s instructions. 
Main steps have considered: 
1. Protein digestion with Digestion Buffer and Proteinase K. 
2. Mix and incubation at 55 °C for 20 min. 
3. Addition of 700 µl of Genomic Lysis Buffer and vortex. 
4. Transference to an extraction column and centrifuge at 10.000 x g for 1 min. 
5. Addition of 200 µl of DNA Pre-Wash Buffer. And centrifuge at 10.000 x g for 1 
min. 
6. Addition of 400 µl of g-DNA Wash Buffer. And centrifuge at 10.000 x g for 1 min. 
7. Addition of 20 µl of DNA Elution Buffer. Incubation at room temperature for 5 
min. and centrifuge at top speed for 30 sec. 
 
 Sample DNA amount was determined by spectrophotometry at 260 nm and DNA 
was stored at -20°C until use. 
 
3.7 DNA Bisulphite Conversion 
 
 The bisulphite modification of DNA samples previously extracted was carried out 
with the EZ DNA Methylation Kit (Zymo Research) according to manufacturer’s 
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instruction (Figure 13). For each conversion reaction, 500 ng of DNA or closest (in case of 
insufficient amount of DNA) was used. Main steps consider: 
 
1. Addition of 5uL of M-Dilution Buffer to DNA sample and addition of Nuclease-
Free water up to 50μL volume.  
2. Incubation at 37 °C for 15 min. 
3. Addition of 100μL of CT Conversion Reagent. 
4. Incubation at 50°C for 12 to 16 hours in the dark. 
5. Incubation of samples at 4 °C (on ice) for 10 min. 
6. Transference of each sample to individual separation columns, containing 400μL of 
M-Binding Buffer. 
7. Centrifuge at top speed for 30 sec. 
8. Addition of 100 µl of M-Wash Buffer and centrifuge at top speed for 30 sec. 
9. Addition of 200 µl of M-Desulphonation Buffer and incubation at room temperature 
for 15-20 min, then centrifuge at top speed for 30 sec. 
10. Addition of 200 µl of M-Wash Buffer and centrifuge at top speed for 30 sec. to 
wash the DNA. This step is repeated once. 
11. Addition of 20 μL of M-Elution Buffer and centrifuge at top speed for 30 sec. to 
release DNA from the resin. 
 
 Converted DNA is ready to use or stored at -80 °C for up to three months. Reported 
reaction conversion efficiency and DNA recovery is up to 99% and 80%, respectively. 
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Figure 13. EZ DNA Methylation procedure (source Zymo Research, 2011). 
 
3.8 MSP Primers 
 
 In order to analyze SEPT9 and NOTCH3 promoter methylation status, MSP primers 
were deigned. 
  
 SEPT9 and NOTCH3 gene sequence was retrieved from online public databases and 
CpG islands were detected upstream in the promoter region (Figure 14). Then, several pairs 
(forward / reverse primers) of suitable sequences were produced due to complementary lost 
between DNA strands after bisulphite conversion (Table 6). 
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Figure 14. Representation of Promoter CpG Islands and potential MSP primers. 
 
 Primers synthesis was requested to CyberGene (CyberGene AB, Stockholm, 
Sweden). 
 
Table 6. SEPT9 and NOTCH3 MSP primers sequence  
Gene  Methylation Status  Direction Sequence ( 5' -> 3' )  
SEPT9 M  F  TTTAAGTTTAAGGAAATCGTAGTATCG  
M  R  AACCACCGAATCTACCTACGAA  
U  F  AATTTTTAAGTTTAAGGAAATTGTAGTATT  
  U  R  CAAACCACCAAATCTACCTACAAA  
NOTCH3  M  F  TTGTTTCGGTTTTAGAGGTGTTC  
M  R  CTTCGCCGAAATAAAACGAC  
U  F  TTTTGGTTTTAGAGGTGTTTGG  
   U  R  CAACTTCACCAAAATAAAACAAC  
M/U = methylated/unmethylated; F/R = Forward/Reverse  
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3.9 rqReal-Time PCR 
 
 For relative quantification (rq) PCR, a SYBR Green based PCR kit was used 
(Maxima SYBR Green/ROX qPCR Master Mix 2x, Fermentas, Thermo Fisher Scientific 
Inc., Waltham, MA, USA). Each 25 µl of PCR reaction contains: 1 µl of eluted bisulphite 
modified DNA (10 ng total DNA), 12.5 µl of SYBR Green PCR Master Mix, 3 µl of F + R 
primer mix (0.3 µM final concentration), and 8.5 µl of DNase-free water. To normalize for 
the amount of input DNA, MYOD gene was used as housekeeping. Two replicates for each 
sample were used. 
 
 rqReal-time PCR conditions were 95 °C for 10 minutes followed by 40 cycles of 95 
° C for 15 s, 50 - 65 °C for 30 s, 72 ° C for 60 s with data acquisition after each cycle in a 
7900HT Fast Real-Time PCR System (Applied Byosistems, CA, USA). Cycle threshold 
(Ct) value of each sample was recorded. 
 
 Amplification products were verified by melting curve analysis (95 °C for 1 min, 55 
°C for 1 min, followed by 80 cycles/10 sec. each of 0.5 °C increasing incubation 
temperature) with data acquisition after each cycle. For additional verification, the correct 
length and purity of PCR products were verified by agarose gel electrophoresis (1.5% 
agarose). 
 
 Methylation percentage was calculated according Lehmann and Kreipe method 
(2004): 1/R + 1 multiplied by 100. Positive control (100% methylated) and standard curves 
were produced using universally methylated/unmethylated DNA (Qiagen, Hilden, 
Germany). 
 
3.10 Statistical analysis 
 
 One way-ANOVA followed by Bonferroni’s multiple comparison test, was used to 
asses statistically significant differences of: MN frequency between Control, Adenoma and 
CRC groups; and MN frequency induced by plasma ultrafiltrate of Control, Adenoma and 
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CRC groups. Given the unknown nature of methylation data, normal distribution was 
evaluated through Shapiro-Wilk normality test. One-way Anova or Kruskall-wallis test, 
followed by Bonferroni or Dunn’s post hoc-test, were used to assess statistically significant 
differences of SEPT9 and NOTCH3 promoter methylation percentage among studied 
groups. MN frequency and induced MN frequency are reported as mean MN ± DS. 
 
 To assess the relationship between peripheral blood lymphocyte MN frequency and 
plasma ultrafiltrate capability to induce MN frequency variations according studied groups, 
linear regression analysis was used. While multiple linear regression analysis was applied 
to assess relationship between SEPT9 and NOTCH3 promoter methylation percentage and 
MN frequency. 
  
 Multinomial logistic regression analysis was performed to evaluate the relative risk 
of different variables over the pathologic status of the study population. 
 
 Descriptive statistic, normality test, One-way ANOVA, Kruskall-Wallis, post hoc 
tests and linear regression analysis were performed using GraphPad Prism 5 (GraphPad 
Software Inc., CA, USA). While multiple linear regression and multinomial logistic 
regression analysis were carried out using R software (Croissant 2011, R development core 
team 2011). 
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4. RESULTS AND DISCUSION 
 
 The age and distribution of gender are fundamental to understand the demographic 
behavior of CRC among population (table 7). The average age considered in the present 
study (MEAN ± DS; controls: 59.3±6; adenoma: 60.43±6.14; CRC: 67.69±9.76 ) is in 
agreement with previous reports of different international cancer organizations, as the 
American Cancer Society and IARC, about the main age related with CRC development. 
But, even when all the subjects considered in this study belong to the age risk population, it 
was possible to observe that CRC group showed a statistically significant higher age not 
only regarding the control (p ≤ 0.001) group, but also regarding the adenoma group (p ≤ 
0.01). This information allows confirming the high correlation between age and risk of 
CRC development often described in literature, and additionally highlights that is possible 
to observe the same trend also inside the age range considered at high risk. The 
female/male ratio between study groups indicate that CRC cases are more common among 
males than females (Table 7), situation that agrees with the same reports of international 
cancer organizations which suggest that this situation will be explained by lifestyle 
differences between both sexes, and the possible protection role that may plays hormones 
as estrogens and progestin (WHO 2000, World Cancer Research Fund 2007). However, the 
same international agencies have hypothesized that in the future sex could be less 
determinant as risk factor due sociologic changes that take place today, such as smoking 
habit or increased women work rate. Indeed, our results show no statistically significant 
differences between sexes regarding CRC condition (Table 7). 
 
 As previously mentioned, in the present study, BMI was included as a biological 
parameter linked to body fatness and it is important to note that BMI range of study 
population, according with the “Clinical Guidelines on the Identification, Evaluation, and 
Treatment of Overweight and Obesity in Adults” (National Heart, Lung and Blood Institute 
1998), was quite narrow (21 – 29) and has excluded obese subjects (≥ 30), which are 
describe as a high risk subpopulation. In fact, no statistically significant differences were 
observed in BMI values among the studied groups. The voluntary condition of the 
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screening program may explain the low participation of obese patients in this kind of 
programs. 
 
 Figure 15 shows the result of the micronuclei analysis, reported as MN 
frequency/1000 Binucleated cells. MN frequency was significantly higher in subjects with 
CRC (17.23 ± 6.3) and adenoma (11.87 ± 3.2) than control (8.3 ± 1.8 ) (p ≤ 0.001 and p ≤ 
0.01, respectively). Also, a statistically significant difference in MN frequency was 
observed between subjects with CRC and adenoma (p ≤ 0.001). This result seems to 
support the concept reported by Bonassi et. al. (2007) and Karaman et al.  (2008) that an 
elevated frequency of MN it is closely related with chromosome damage often observed in 
carcinogenic process. Furthermore, a wide range of studies indicate that CRC progress 
through the accumulation of several genetic changes even at the earliest stages of the 
disease, thus this results suggest that MN frequency varies following CRC dynamics 
through the different main stages of this pathology (Carethers 1996, Lengauer et al. 1998, 
Karaman et al. 2008, Bousserouel et al. 2010). 
 
 Indeed, the Relative Risk associated with the different variables considered in the 
study (Table 8), assessed by multinomial logistic regression analysis in a theoretical model 
which includes MN frequency, age, gender, BMI and smoke habit, indicates that an 
elevated MN frequency leads to a 71% increased risk to develop adenoma and when 
associated with an elevated age, it leads to a 113% increased risk for CRC, considering 
Control group as reference. Several Authors have indicated that age is strongly related with 
MN fomation (Iamarcovai et al. 2006, Bonassi et al. 2007, Karaman et al. 2008) and seems 
logic to think that age plays, in the suggested model, not only a role in CRC risk but also in 
MN formation. To evaluate this situation, the influence of the different variables considered 
in the study on the MN frequency was assessed by multiple linear regression analysis 
(Table 9), and even when a positive and statistically significant correlation was found 
between age and MN, age variation was able to explain only 29% of the variation observed 
for MN frequency, suggesting underlying mechanisms that lead to an increased MN 
frequency among adenoma and CRC subjects. Additionally, Fenech et al. (2011) have 
pointed that age plays a significant role in spontaneous MN frequency and described a 
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monotonically increase in MN frequency over 30 years. However, for the last decades (≥ 50 
years) the rate of the increase seems similar and age influence seems to be lower, fact that 
is consistent with our data. 
 
 Regarding the other variables, (gender, BMI and smoke habit) none of them shows 
influence over pathologic status (Table 8), even when all have been described as risk factor 
for CRC. As previous mentioned, and as proposed by several international agencies, 
sociologic changes may have altered the influence of gender and further studies must be 
conducted to elucidate the real contribution of gender to this particular disease. About BMI, 
Ning et al. (2010) have reported a strong relationship between colon CRC and this variable, 
and an 18% increased risk each 5 kg/m2 of BMI gain. On the other hand, smoke habit has 
been described as one of the most critical factors related with CRC, regrettably, the 
proportion of never smokers and ex/currently smokers was not ideal and the lack of the 
latter has influenced the results regarding this variable. It is possible to hypothesize that the 
voluntary character of the screening program may be negatively influenced obese and 
ex/current smokers to avoid participate in the program. 
 
 About, CF-MN analysis (Figure 16), a statistically significant difference was 
observed between CRC (8.8 ± 3.5) and control (6.6 ± 1.9) (p ≤ 0.05). Several authors have 
pointed the mechanism that lead to spontaneous MN formation (Fenech et al. 2011) and 
Lindholm et al. (2010) have suggested that plasma ultrafiltrated from patients affected by 
different diseases can induce MN formation through clastogenic activity. Our results allow 
hypothesize the same kind of activity in the plasma ultrafiltrate from CRC subjects. 
Furthermore, the use of 10 KDa cutoff filter enhance the importance of small molecules in 
generation and perpetuation of genetic damage. Moreover, as for spontaneous MN 
frequency, we test the influence of previously studied variables on plasma utrafiltrate 
capacity to induce MN formation (Table 10) being observed that none of the variables was 
related with this capacity, suggesting that the same underlying mechanism which lead to 
spontaneous MN formation are related with plasma constituents being able to induce 
genetic damage. This situation was later confirmed when relationship between spontaneous 
MN frequency and CF-MN frequency was tested (Figure 17) and a positive correlation 
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founded (0.33, p ≤ 0.001). Traditionally, clastogenic activity has been assessed by 
chromosome aberration analysis and only in recent years micronuclei has been 
demonstrated as a reliable indicator (Lindholm et al. 2010), however, as previously 
mentioned, both aneuploidy and clastogenic events can induce micronuclei formation, thus, 
further analysis, such as fluorescence in situ hybridization, must be applied in order to 
effectively establish the mechanism that lead to an increased micronuclei count (Fenech M. 
2011). Even when further studies must be conducted to elucidate if this plasma factors 
induce genetic damage through clastogenic or aneuplodogenic mechanisms, it’s possible to 
hypothesize that CF should be considered not only as an oxidative stress biomarker (Emerit 
2007, Maffei et al. 2011), but also as an active agent which could perpetuate and even 
enhance the genetic damage observed in the carcinogenic process. 
 
 Regarding MSP analysis, it was observed that methylation level, in percentage, of 
SEPT9 promoter region was statistically significant lower in CRC subjects (60.14 ± 23.66)  
respect controls (79.71 ± 16.24) (p ≤ 0.01). On the other hand, methylation level in CaCo2 
cells, for the same gene, was close to 100% (97.94) (Figure 18). Although these results 
appear contradictory, they are in agreement with what reported in literature. Scott et al. 
(2005) have observed an overexpression of SEPT9 in different tissues, included the hematic 
one, in different types of cancer, while at CRC tissue specific level, deVos et al. (2009) 
have detected an hypermethylation of the promoter region of this gene. Considering that 
DNA methylation is associated with gene silencing and the loss of methylation leads to 
overexpression of the same gene, our results reflects the same situation. Recently, Hanahan 
and Weinberg (2011) have highlighted that immune system plays a critical role in 
tumorigenesis, and indicate that leukocytes acts as tumor antagonizing but also as tumor 
promoters, and that this situation was largely unanticipated. Our results seem to support this 
idea mainly because leukocytes are the main source of genomic DNA available in a whole 
blood sample, and if it considered that neutrophils and lymphocytes are the most numerous 
cells of the circulating leukocytes, and the main cells called to infiltrate tumors (Hanahan 
and Weinberg 2011); and that the loss of methylation level of SEPT9 could be interpreted 
as SEPT9 upregulation, it is possible to hypothesize that in CRC subjects SEPT9 
expression could suggest a critical immune activity related to the growing early tumor, but 
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without indicate if this activity is related with antagonizing or promoter behavior. On the 
other hand, the hypermethylated status of SEPT9 promoter at tissue specific level could be 
explained because cells in colon epithelium undergo division and differentiation from the 
cript to the villous apex, and the silencing of SEPT9 can induce cell cycle and cytokinesis 
alterations, considering the functions described for this gene (Peterson et al. 2011). 
However, as pointed by several Authors, SEPT9 gene corresponds to a very complex gene 
with several expression variants due alternative splicing (Connolly et al. 2011), and even 
when some functions have been described for it, others are expected to emerge in the 
future. The mechanism of action and cross-talk with different cell pathways are mainly 
unknown. 
 
 For NOTCH3, MSP analysis has shown statistically significant differences between 
studied goups. Control NOTCH3 promoter methylation level (63.32 ± 6.06) was 
significantly higher than adenoma (49.31 ± 6.2) (p ≤ 0.001) and CRC (30.51 ± 12.65) (p ≤ 
0.001). Additionally, adenoma NOTCH3 promoter methylation level (49.31 ± 6.2) was 
significantly higher than CRC (30.51 ± 12.65) (p ≤ 0.001). NOTCH3 promoter methylation 
level was extremely low (≈ 1%) in the adenocarcinoma cell model. Although the 
information available regarding NOTCH3 and its role in the carcinogenic process is not 
abundant, these results also support the concept proposed by Hanahan and Weinberg (2011) 
about an immune role in tumorigenesis, but suggesting an immune activity also related with 
adenoma formation. The low level of promoter methylation of this gene in the cell line 
agrees with the information reported in several publications, which indicate that NOTCH3 
through NOTCH3 signaling pathway is highly expressed in normal colon-rectum 
epithelium (Miyamoto and Rosenberg 2011) and its overexpression is not only related with 
tumor growth, but also with aggressive CRC (Serafin 2011). 
 
 Finally, through multiple regression analysis was possible to establish a negative 
correlation between spontaneous MN frequency and methylation levels of SEPT9 and 
NOTCH3 promoter region (Table10). More clearly, the increase in MN frequency may 
correlate with the decrease in methylation level of the promoter region of these genes. In 
literature is not possible to find such comparison, but considering the information 
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previously mentioned and the available information regarding functions of these genes and 
how their expression lead to genomic instability, through aneuploidy phenomena, in the 
case of SEPT9, and to hyperproliferation in the case of NOTCH3, it could be hypothesized, 
as suggested by Hanahan and Weinberg (2011), that the immune system can act initially as 
a tumor antagonist but, because of infiltration once the damage it is well establish and the 
interaction with tumorigenic components of tumor microenvironment enhanced by the 
same immune response, it becomes to act not only as a direct tumorigenic component but 
also as a tumor promoter. However, the information available about this matter is poor and 
further studies must be conducted in order not only to answer this specific question but to 
investigate, for example, its role in other areas of carcinogenesis, like metastasis.  
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Table 7. Demographic characteristics of the study population. 
 CONTROL ADENOMA CRC 
Subjects 26 23 26 
Age 59.3±6 60.43±6.14 67.69±9.76 (a, b) 
Gender 
F/M 
7/19 10/13 10/16 
BMI 25.73±3.27 26.87±3.09 24.45±3.53 
Smoke 
N/ES 
19/7 18/5 18/8 
Gender F/M, Females/Males; BMI, Body Mass Index; Smoke N/ES, Never/Ex or current 
Smoker. a) Statistically significant difference vs control group (p ≤ 0.001). b) Statistically 
significant difference vs adenoma group (p ≤ 0.01). 
 
 
 
 
Figure 15. MN Frequency in peripheral blood lymphocytes of study groups. Mean MN ± 
DS; control: 8.3 ± 1.8; adenoma: 11.87 ± 3.2; CRC: 17.23 ± 6.3. Statistically significant 
difference vs control group (p ≤ 0.001); b) Statistically significant difference vs control 
group (p ≤ 0.01); c) Statistically significant difference vs adenoma group (p ≤ 0.001). 
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Table 8. Relative Risk associated to MN frequency, age, gender, BMI and smoke habit. 
Control as the reference group. 
GROUP  MN AGE  GENDER BMI  SMOKE 
ADENOMA  1.71 *** 1.01 0.55 1.11 1.06 
CRC  2.13 *** 1.14 * 0.94 0.95 1.58 
*** statistically significant, p ≤ 0.001. * statistically significant, p ≤ 0.05. r^2 = 0.4. 
 
 
 
 
 
 
Table 9. Influence of age, gender, BMI and smoke habit in MN formation. 
Variable β p 
Age 0.33 ≤ 0.001 
Gender -1.9 0.12 
BMI -0.14 0.41 
Smoke 2.07 0.13 
Multiple Correlation Coefficient  0.538 
Determination Coefficient  0.29 
p ≤ 0.05 was considered statistically significant. 
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Figure 16. CF-MN Frequency induced by plasma ultrafiltrate of the studied groups over 
peripheral blood lymphocytes from an healthy donor. Mean MN ± DS; control: 6.6 ± 1.9; 
adenoma: 7.1 ± 2.5; CRC: 8.8 ± 3.5. Statistically significant difference between CRC and 
control group (p ≤ 0.05). 
 
 
 
 
 
Table 10. Influence of Age, Gender, BMI and smoke habit in MN formation induced by 
plasma ultrafiltrate. 
Variable β p 
Age 0.06 0.1 
Gender -0.59 0.4 
BMI -0.08 0.4 
Smoke -0.61 0.4 
Multiple Correlation Coefficient  0.283 
Determination Coefficient  0.08 
p ≤ 0.05 was considered statistically significant. 
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Figure 17. Linear Regression Analysis of MN Frequency and CF-MN frequency. 
Correlation coefficient = 0.57 (p ≤ 0.001). 
 
 
 
 
 
Figure 18. Whole blood DNA SEPT9 promoter methylation status among studied groups. 
CaCo2 cells has been included as an adenocarcinoma cell model. Control: 79.71 ± 16.24; 
adenoma: 71.42 ± 22.32; CRC: 60.14 ± 23.66; CaCo2: 97.94. Statistically significant 
difference between CRC and control group (p ≤ 0.01). 
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Figure 19. Whole blood DNA NOTCH3 promoter methylation status among studied 
groups. CaCo2 cells has been included as an adenocarcinoma cell model. Control: 63.32 ± 
6.06; adenoma: 49.31 ± 6.2; CRC: 30.51 ± 12.65; CACO2: 1. Statistically significant 
difference between: a) adenoma and control (p ≤ 0.001); b) CRC and control (p ≤ 0.001); c) 
CRC and adenoma (p ≤ 0.001). 
 
 
 
Table 10. Influence of SEPT9 and NOTCH3 promoter methylation stauts on MN frequency 
among the studied groups. 
GENE β p 
SEPT9 -0.07 0.04 
NOTCH3 -0.16 ≤ 0.0001 
Multiple Correlation Coefficient  0.61 
Determination Coefficient  0.38 
p ≤ 0.05 was considered statistically significant. 
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5. CONCLUSIONS 
 
 CRC has been described as a leading cause for cancer-related death worldwide, but  
even when CRC is one in the small group of cancers which can be prevented by screening, 
compliance to screening test remain lower. Main efforts have been made to increase 
screening rates among population at risk for CRC thus the identification and development 
of new markers obtained from easily accessible tissues, leading to a less invasive screening 
test, have become of great importance. 
 
The research has evaluated potential cellular and molecular biomarkers related with 
CRC risk. The results obtained allow to conclude that MN frequency varies according CRC 
pathologic status and, together with other variables, may be considered a valid biomarker 
for adenoma and CRC risk. Additionally, the plasma of patients affected with CRC not 
only serves as a biomarker for oxidative stress, but also as a biomarker of genetic damage 
correlated with the carcinogenic process that verifies in the colon-rectum. 
 
 On the other hand, it is possible to conclude that SEPT9 gene is downregulated in 
CRC at tissue specific level, but upregulated in whole blood cells of CRC positive subjects. 
In the same way, NOTCH3 is upregulated in both adenoma and CRC affected subjects, at 
whole blood cells level. Furthermore, SEPT9 and NOTCH3 promoter methylation status, at 
whole blood cells level, varies according hystopatholigal changes observed in colon-
rectum, suggesting that promoter methylation status of these genes could be a reliable 
biomarker for CRC risk. Finally, the presence of a relationship between SEPT9 and 
NOTCH3 promoter methylation status and spontaneous MN frequency not only suggests a 
direct role of these genes in the genesis of MN, but also suggests a possible explanation for 
the tumor promoter activity described for the immune system. 
 
 Even if further studies must be conducted, the evidence presented supports the 
concept that biomarker research, at cellular and molecular level, can provide new 
perspectives in detection, prevention and prognosis not only for Colorectal Cancer, but for 
the carcinogenic process in general. 
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7. ADDENDUM 
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